RxDoctor Payments Data

Kathryn Wilson, DO

Optometrist · Somerset, KYNPI 1851777825

Payments from drug & device makers

$2,673in general payments, 2019–2025

Across 26 payments — averaging $102.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Johnson & Johnson Vision Care, Inc.$398
  • Bausch & Lomb Americas Inc.$212
  • AbbVie$119
  • Tarsus Pharmaceuticals, Inc.$24
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$21
  • plus $32 from 2 others

What the payments were for

  • Travel & lodging$1,35851%
  • Food & beverage$1,31549%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,673 in reported general payments places this provider in the 80th percentile of 712 optometrist providers in Kentucky.

See all optometrist providers in Kentucky

Medicare billing

Part B allowed, 2024
$59,800
Medicare patients
380
Services billed
1,448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost46$23,057
RestasisCyclosporine11$20,404
XiidraLifitegrast26$19,653
RhopressaNetarsudil Mesylate20$6,244
Alphagan PBrimonidine Tartrate11$2,292
Travoprost22$2,239
Prednisolone Acetate41$1,178
Latanoprost90$493
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat37$294
Brimonidine Tartrate19$217
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha17$206
Timolol Maleate14$4

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$119$45,75268 claims
Bausch & Lomb Americas Inc.Xiidra$212$19,65326 claims
Aerie Pharmaceuticals, Inc.Rhopressa$20$6,24420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 712 optometrist providers in Kentucky.

Other optometrist in Somerset

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →